Curie Institute 
Welcome,         Profile    Billing    Logout  
 1 Product   11 Diseases  1 Product   6 Trials   202 News 
9 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
gedatolisib (PF-05212384) / Celcuity
VIKTORIA-1, NCT05501886: Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer

Recruiting
3
701
Europe, Canada, US, RoW
Gedatolisib, PF-05212384, PKI-587, Palbociclib, IBRANCE, PD-0332991, Fulvestrant, Faslodex, Alpelisib, Piqray, Vijoice, BYL719
Celcuity, Inc.
Breast Cancer
09/24
09/26
VIKTORIA-1, NCT05486143: Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer

Recruiting
3
701
US, RoW
Gedatolisib, PF-05212384, PKI-587, Palbociclib, IBRANCE, PD-0332991, Fulvestrant, Faslodex, Alpelisib, Piqray, Vijoice, BYL719
Celcuity, Inc.
Breast Cancer
09/25
09/26
2014-003811-13: Improving treatment selection in patients with cancer using a personalized screening test Het beter selecteren van een behandeling voor patiënten met kanker met behulp van een gepersonaliseerde screening test.

Ongoing
2
70
Europe
Palbociclib, Axitinib, Selumetinib, Gefitinib, PD-0332991, PF-04449913, PF-05212384, AG-013736, AZD6244, AZD2014, AZD5363, ZD1839, Capsule, hard, Tablet, Lyophilisate for solution for infusion, Capsule, Inlyta, Iressa
Antoni van Leeuwenhoek - Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital - Netherlands Cancer Institute, Pfizer Inc., AstraZeneca
Colorectal cancer and non-small cell lung cancer colorectaal carcinoom en niet-kleincellig longkanker, colorectal cancer and lung cancer Dikkedarmkanker en longkanker, Diseases [C] - Cancer [C04]
 
 
KCSG-BR18-13, NCT03698383: Phase II Study of Herzuma® Plus Gedatolisib in Patients With HER-2 Positive Metastatic Breast Cancer

Recruiting
2
15
RoW
Trastuzumab biosimilars(Herzuma), Gedatolisib, Herzuma plus Gedatolisib
Korean Cancer Study Group
HER2-positive Breast Cancer, Metastatic Breast Cancer
10/21
12/21
BTCRC-BRE18-337, NCT03911973: Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers

Active, not recruiting
1/2
37
US
Gedatolisib, Talazoparib
Kari Wisinski, Pfizer, Celcuity Inc
TNBC - Triple-Negative Breast Cancer
07/24
07/24
CELC-G-201, NCT06190899: Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer

Recruiting
1/2
54
Europe, US
Gedatolisib, Darolutamide, NUBEQA
Celcuity Inc
mCRPC (Metastatic Castration-resistant Prostate Cancer), Genital Diseases, Male, Urogenital Diseases, Male, Prostatic Disease, Prostatic Neoplasms, Castration-Resistant, Prostate Cancer
11/25
11/27
NCT02626507: Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer

Checkmark gedatolisib plus Ibrance in ER+/HER2- metastatic breast cancer
Apr 2021 - Apr 2021: gedatolisib plus Ibrance in ER+/HER2- metastatic breast cancer
Active, not recruiting
1
18
US
Gedatolisib, Code name PF-05212384, PKI-587, Faslodex, Fulvestrant, Palbociclib, Ibrance, Zoladex, goserelin
Hoffman Oncology, DSCS CRO
Breast Cancer
02/22
03/22
NCT03065062: Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors

Hourglass Jan 2019 - Dec 2019 : In combination with gedatolisib for PIK3CA mutated tumors
Recruiting
1
96
US
Palbociclib, IBRANCE, PD-0332991, Gedatolisib, PF-05212384
Dana-Farber Cancer Institute, Pfizer
Lung Cancer Squamous Cell, Solid Tumors, Head & Neck Cancer, Pancreatic Cancer
01/25
01/26
NCT05134922: Expanded Access Protocol for Subjects Previously Treated With Gedatolisib in B2151009

Available
N/A
US
Gedatolisib
Celcuity, Inc.
Breast Neoplasm Malignant Female
 
 
synthetic humanised camelid CTLA4 inhibitor nanobody / TheraVectys
No trials found
synthetic humanised camelid single-domain CD27 inhibiting antibody / TheraVectys
No trials found
ELB031 / Mediolanum Pharma, Curie Institute
No trials found
CAR T cell therapy / Mnemo Therap
No trials found

Download Options